Table 2.
Cox regression analysis of overall survival in the independent CQ validation cohort
| Histology | Variable | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|
| HR(95% CI) | P value | HR(95% CI) | P value | ||
| ADC | Six-protein signaturea | 2.89 (1.52–5.48) | 0.001 | 3.07 (1.29–7.32) | 0.011 |
| Stageb | 2.43 (1.64–3.60) | < 0.001 | 2.43 (1.46–4.03) | 0.001 | |
| Age > 60 years | 1.33 (0.70–2.53) | 0.390 | 1.37 (0.65–2.87) | 0.413 | |
| Tumor size | 1.09 (0.91–1.30) | 0.341 | 1.02 (0.84–1.24) | 0.880 | |
| Smoking index | 1.01 (0.99–1.03) | 0.425 | 0.99 (0.97–1.01) | 0.426 | |
| Chemotherapy | 1.09 (0.52–2.30) | 0.816 | 1.50 (0.61–3.67) | 0.379 | |
| SCC | Five-protein signaturea | 10.84 (4.15–28.31) | < 0.001 | 7.84 (2.88–21.31) | < 0.001 |
| Stageb | 2.85 (1.78–4.57) | < 0.001 | 2.24 (1.26–3.99) | 0.006 | |
| Age > 60 years | 1.73 (0.86–3.50) | 0.127 | 1.48 (0.70–3.14) | 0.307 | |
| Tumor size | 1.15 (1.00–1.32) | 0.058 | 1.02 (0.85–1.23) | 0.838 | |
| Smoking index | 1.00 (0.99–1.01) | 0.994 | 1.00 (0.98–1.02) | 0.659 | |
| Chemotherapy | 1.23 (0.56–2.71) | 0.615 | 1.45 (0.55–3.83) | 0.452 | |
ADC, adenocarcinoma; SCC, squamous cell carcinoma; HR, hazard ratio
aCompared with low-risk group. bModeled as a continuous variable